"CONCLUSIONS BNT162b2-induced protection against SARS-CoV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine–Qatar and others.)"
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar"
“protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine–Qatar and others.)”
I think that was their point, it’s the time period after 6 months that degradation of the immune system begins to appear.
“Nothing in the conclusion of the study that says anything about immune system degradation or inability to fight off other diseases. “
Thanks for actually reading the study, it also says the vaccine was 96% effective against death after 2 months.
“Estimated BNT162b2 effectiveness against any severe, critical, or fatal disease due to any SARS-CoV-2 infection was negligible for the first 2 weeks after the first dose. It increased rapidly to 66.1% (95% CI, 56.8 to 73.5) in the third week after the first dose and reached 96% or higher in the first 2 months after the second dose (Table 2 and Figure 2B). Unlike effectiveness against infection, effectiveness against hospitalization and death did not decline over time, except possibly in the seventh month after the second dose when there was a hint of a decline, but the case numbers were small. “